A practical reference on Selank: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-12 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
The scandal began with revelations of contamination of Sanlu milk products. The New Zealand dairy cooperative Fonterra, which owned a 43% stake in Sanlu, said they were alerted to melamine contamination on 2 August (almost a month before the issue became public), and have said to have pushed hard for a full public recall. Although there was an immediate trade recall, Fonterra said that local administrators refused an official recall. A Fonterra director had given Sanlu management a document detailing the European Union's permitted levels of melamine, but Fonterra chief executive Andrew Ferrier has stated that at no time did Fonterra say small amounts of melamine were acceptable.
=== Reversing the mechanism === The antioxidant N-acetyl-L-cysteine (NAC) is known to significantly reduce the cytotoxicity induced by DCBQ. NAC is a precursor of sulfhydryl-containing tripeptide glutathione (GSH), which is produced and kept at high levels in all cells, helping them defend against oxidative stress. Once NAC is inside the cell, it is rapidly hydrolyzed to cysteine so that it can be used to form GSH. Restoring the high GSH levels in the cell. NAC is available in oral, inhalation, and intravenous (IV) formulations.
=== Nucleotides === Containing both amines or imines and phosphoric acid groups, the nucleotides such as AMP, ADP, and ATP exist significantly as zwitterions, although the positive and negative charges are not necessarily balanced.
The same is true for vessels in air: a dirigible that weighs 100 tons needs to displace 100 tons of air. If it displaces more, it rises; if it displaces less, it falls. If the dirigible displaces exactly its weight, it hovers at a constant altitude. While they are related to it, the principle of flotation and the concept that a submerged object displaces a volume of fluid equal to its own volume are not Archimedes' principle. Archimedes' principle, as stated above, equates the buoyant force to the weight of the fluid displaced. One common point of confusion regarding Archimedes' principle is the meaning of displaced volume. Common demonstrations involve measuring the rise in water level when an object floats on the surface in order to calculate the displaced water. This measurement approach fails with a buoyant submerged object because the rise in the water level is directly related to the volume of the object and not the mass (except if the effective density of the object equals exactly the fluid density).
Sources: en.wikipedia.org
== History == Insulin was introduced by Frederick Banting and Charles Best from the University of Toronto in 1921 as an injectable agent. Researchers first reported the concept of "smart insulin patch" in 2015. The prototype of smart insulin patch "was demonstrated as a continuous glucose control in a type 1 diabetic mouse model. As of 2019, glucose-responsive insulin patches are becoming more common. In 2020, scientists at UCLA and Zenomics Inc. developed "Smart Insulin Patch 2.0" and validated its feasibility in a diabetic minipig model. Currently, Zenomics is applying for U.S. Food and Drug Administration (FDA) approval for first-in-human trials and the technology has been accepted into the FDA's Emerging Technology Program.
== External links == PROK1+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) PROK2+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
=== FSEC-TS === In fluorescence-detection size exclusion chromatography the protein of interest is fluorescently tagged (e.g., with GFP) and run through a gel filtration column on an FPLC system equipped with a fluorescence detector. The resulting chromatogram allows the researcher to estimate the dispersity and expression level of the tagged protein in the current buffer. Since only fluorescence is measured, only the tagged protein is seen in the chromatogram. FSEC is typically used to compare membrane protein orthologs or screen detergents to solubilize specific membrane proteins in. For fluorescence-detection size-exclusion chromatography-based thermostability assay (FSEC-TS) the samples are heated in the same manner as in FastPP and CETSA and following centrifugation to clear away precipitate the supernatant is treated in the same manner as FSEC. Larger aggregates are seen in the void volume while the peak height for the protein of interest decreases when the unfolding temperature is reached. GFP has a Tm of ~76 °C so the technique is limited to temperature below ~70 °C.
The time-of-flight principle can be applied for mass spectrometry. Ions are accelerated by an electric field of known strength. This acceleration results in an ion having the same kinetic energy as any other ion that has the same charge. The velocity of the ion depends on the mass-to-charge ratio. The time that it subsequently takes for the particle to reach a detector at a known distance is measured. This time will depend on the mass-to-charge ratio of the particle (heavier particles reach lower speeds). From this time and the known experimental parameters one can find the mass-to-charge ratio of the ion. The elapsed time from the instant a particle leaves a source to the instant it reaches a detector.
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the pyridopyrroloquinoxaline and butyrophenone families. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate), and for major depressive disorder as an adjunctive therapy only (with an oral antidepressant). It is developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb. Lumateperone was approved for medical use in the US in December 2019 with an initial indication for schizophrenia. It became available in February 2020.
Sources: en.wikipedia.org
==== Distribution ==== Enobosarm is a small-molecule and highly lipophilic compound. Compounds of this type are typically able to diffuse freely through biological membranes such as cell membranes and barriers like the blood–brain barrier. This is in fact essential for the action of nuclear receptor ligands like enobosarm since their biological targets (the androgen receptor in this case) are located intracellularly. One in silico study predicted that, on the basis of its overall physicochemical properties (but not considering active transport), enobosarm would be unlikely to cross the blood–brain barrier and hence would be a peripherally selective drug with reduced or no central nervous system effects. However, in a rat tissue distribution study, enobosarm was found to be concentrated in brain tissues to a similar extent as other target tissues like skeletal muscle, bone, prostate, and seminal vesicles. This is consistent with enobosarm producing centrally mediated effects in humans like suppression of LH and FSH secretion. Enobosarm does not bind to sex hormone-binding globulin.
=== Modes of toxicity === Since silver nanoparticles undergo dissolution releasing silver ions, which is well-documented to have toxic effects, there have been several studies that have been conducted to determine whether the toxicity of silver nanoparticles is derived from the release of silver ions or from the nanoparticle itself. Several studies suggest that the toxicity of silver nanoparticles is attributed to their release of silver ions in cells as both silver nanoparticles and silver ions have been reported to have similar cytotoxicity. For example, In some cases it is reported that silver nanoparticles facilitate the release of toxic free silver ions in cells via a "Trojan-horse type mechanism", where the particle enters cells and is then ionized within the cell. However, there have been reports that suggest that a combination of silver nanoparticles and ions is responsible for the toxic effect of silver nanoparticles. Navarro et al. using cysteine ligands as a tool to measure the concentration of free silver in solution, determined that although initially silver ions were 18 times more likely to inhibit the photosynthesis of an algae, Chlamydomanas reinhardtii, but after 2 hours of incubation it was revealed that the algae containing silver nanoparticles were more toxic than just silver ions alone. Furthermore, there are studies that suggest that silver nanoparticles induce toxicity independent of free silver ions. For example, Asharani et al.
7 July Starmer makes his first visit to Scotland as prime minister, for a meeting with First Minister John Swinney. Lewis Hamilton of Mercedes takes his ninth victory at the British Grand Prix, breaking the record for the most wins at a single circuit and Grand Prix, and the most wins at a driver's home Grand Prix, bringing an end to a 56 winless race streak and making him the first driver to win a race after their 300th Grand Prix start. 8 July The Chancellor, Rachel Reeves, announces new housebuilding targets for England, and the loosening of planning rules to encourage more new homes. The ban on onshore wind in England is lifted. 9 July Minister Jim McMahon tells BBC News that the phrase "levelling-up" will be replaced with "local government" and that his department will now be named the Ministry of Housing, Communities and Local Government. Health Secretary Wes Streeting begins talks aimed at ending a long-running pay dispute with junior doctors in England. Starmer holds his second cabinet meeting, after telling England's regional mayors he will meet with them regularly to help growth across the UK. The first meeting of the 59th Parliament of the United Kingdom takes place. Vacuum manufacturer Dyson announces it is cutting a third of its UK workforce as part of a global restructuring strategy. 10 July Starmer travels to Washington, D.C., his first foreign trip as UK Prime Minister, to attend the 75th NATO summit.
== Society and culture == Many societies have a system for organ donation, in which a living or deceased donor's organ are transplanted into a person with a failing organ. The transplantation of larger solid organs often requires immunosuppression to prevent organ rejection or graft-versus-host disease. There is considerable interest throughout the world in creating laboratory-grown or artificial organs.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.